Navigation Links
Tumor in Medical Technology

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

Promising Anti-cancer Activity Observed in Relapsed Patients ORLANDO, Fla., and SOUTH SAN FRANCISCO, Calif. , May 30 /PRNewswire/ -- Proteolix, Inc. today reported on clinical advances for its carfilzomib solid tumor program in an oral presentation at the 2009 Annual Meeting of the American S...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

Clinical Data Presented at the 2009 ASCO Meeting INDIANAPOLIS, May 30 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I clinical trial of its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut - Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced...

Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology

- Progression-Free Survival Data to be Presented for Phase 2 Colorectal and Prostate Trials - - Company to Hold Investor Event on Sunday, May 31 with Oncology Experts - SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ) today ann...

Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin

Identifies potential clinical trial strategies for personalized approach to cancer treatment SEATTLE, April 21 /PRNewswire-FirstCall/ -- Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC), presented data from a preclinical study, whic...

New Imaging Analysis Predicts Brain Tumor Survival

U-M researchers develop 'parametric response map' to analyze changes in a tumor's blood flow, volume ANN ARBOR, Mich., April 20 /PRNewswire-USNewswire/ -- As early as one week after beginning treatment for brain tumors, a new imaging analysis method was able to predict which patients would li...

Discovery of Marker for Colon Stem Cells Could Shed Light on What Drives Tumor Growth

WILMINGTON, Del., April 7 /PRNewswire/ -- Cancer researchers led by Bruce Boman, M.D., Ph.D. director of Cancer Genetics and Stem Cell Biology at the Helen F. Graham Cancer Center of the Christiana Care Health System, and a faculty member at the University of Delaware , have discovered an enzyme ...

Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting

THE WOODLANDS, Texas, March 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Dr. Philip Brown , senior vice president of clinical develop...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

- Data show significant 66% reduction in risk of disease progression versus placebo - Sandostatin LAR more than doubled time without tumor growth for a median of 14 months compared to six months on placebo - Results support Sandostatin LAR as first treatment after surgery in certain pati...

Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source

St. Jude scientists show for the first time that normal stem cells can act as the source of tumors in mature solid tissues MEMPHIS, Tenn., Dec. 17 /PRNewswire-USNewswire/ -- Scientists at St. Jude Children's Research Hospital have answered a central question in cancer biology: whether n...

Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome

- Results Presented at ASH Annual Meeting- SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological mali...

Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer

MARSEILLE, France, November 24 /PRNewswire-FirstCall/ -- IPSOGEN SA (Marseille, France and New Haven, CT, USA), a cancer profiler that markets molecular diagnostic assays for leukemia and breast cancer announced today the European launch of MapQuant Dx(TM) HER2 test. Developped on the MapQuant Dx(...

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies

SAN MARINO, Calif., Nov. 20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meet...

Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy

Quark siRNAs Examined Alone and in Combination with Chemotherapy FREMONT, Calif. Oct. 12 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that the journal Cance...

St. Jude Study Finds Treatment With New Drug Might Make Tumor Cells More Sensitive to Therapy

Study shows treatment with a newly discovered drug could be useful in sensitizing tumor cells to therapeutic irradiation and potentially some chemotherapies MEMPHIS, Tenn., Sept. 16 /PRNewswire-USNewswire/ -- Scientists at St. Jude Children's Research Hospital have shown that it might be pos...

Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer

- New data, updated since ASCO, show time without tumor growth now reaches nearly 5 months with RAD001 vs. 1.9 months with placebo - One quarter of patients in trial remained progression-free beyond ten months of treatment - RAD001 is first drug to show significa...

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

First T cell engaging antibody (BiTE) showing clinical benefit in cancer patients; Blinatumomab enables patients own T cells to recognize and attack cancer cells BETHESDA, Md., Aug. 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical c...

Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer

Data Support Prognostic Value of Circulating Tumor Cells RARITAN, N.J., July 25 /PRNewswire/ -- An international, prospective clinical trial found the number of circulating tumor cells (CTCs) is a strong indicator of progression-free and overall survival among metastatic colorectal cancer pa...

Children's Brain Tumor Foundation's Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research

Leading Institutions in Philadelphia, Pittsburgh and Chicago To Launch Collaborative Initiative NEW YORK, July 1 /PRNewswire-USNewswire/ -- In a major effort to speed treatment and cures for pediatric brain tumors and cancer, the Children's Brain Tumor Foundation (CBTF) today launched the in...

Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test

- Significant Milestone Achieved Based on Compelling Clinical Studies - Company to Host Roundtable Conference Call on July 15 FREMONT, Calif., June 25 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML ), a molecular diagnostics company, today announced that it has submitted a 5...

SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation

DUBLIN, Calif., June 16 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced at the 13th Congress of the European Hema...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

DUBLIN, Calif., June 13 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced at the 13th Congress of the European Hema...

New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting

WAYNE, N.J. and EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced the presentation of new clinical data from the early clinical trials in the development program for Nexavar(R) (sorafenib)...

Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer

- Poster Presented at ASCO Annual Meeting - SOUTH SAN FRANCISCO, Calif. and CHICAGO, June 1 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced safety and efficacy results from a previously unp...

TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)

SAN MARINO, Calif., May 27 /PRNewswire/ -- Epeius Biotechnologies ( http://www.epeiusbiotech.com ) announced today that the results of a Phase I Feasibility Study of sequential targeted gene delivery -- using Rexin-G followed by Reximmune-C -- for cancer vaccination will be presented at the AS...

Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited

NEW YORK, May 20 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH ) announced that Richard Taney, President and Chief Executive Officer, provided an update on enrollment numbers in the Company's pivotal Phase III clinical trial today at a gathering of financial and healthcare ind...

RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer

- RECORD-1 trial shows RAD001 reduces risk of disease progression by 70% - RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent(R) or Nexavar(R),** with potential to address unmet medical need - Once-daily oral RAD001 di...

Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting

- Safety and Efficacy Clinical Data from Prostate, Colorectal and Ovarian Cancers - - Company to Hold Investor Event on Sun., June 1 with Oncology Experts - SOUTH SAN FRANCISCO, Calif., May 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD...

Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer

SAN DIEGO and SUNNYVALE, Calif., April 16 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today presented preclinical results demonstrating the anti-tumor activity of PCI-27483, the company's small-molecule Factor VIIa inhibitor. The data were presented during the Annual Meeting...

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models

DUBLIN, Calif., April 16 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at ...

Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer

-No Metastatic Lesions Were Detectable After Combination Therapy Treatment- -Survival Time More Than Doubled in Animals Treated with Combination Therapy- -Established Tumors Regressed by 50% After Combination Therapy Treatment- SAN DIEGO and TUSTIN, Calif., April...

BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies

- BiPar Sciences Presents First Peer-Reviewed Preclinical Results for BSI-201 at 2008 AACR Annual Meeting - SAN DIEGO, April 14 /PRNewswire/ -- BiPar Sciences, Inc. today announced positive preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PAR...

New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume

KGK Synergize Inc. Presents Findings Today SAN DIEGO, April 7, 2008 /PRNewswire/ -- A new study presented at the Experimental Biology Annual Meeting shows that a proprietary blend extracted from canola, Dermytol(TM), produces a pronounced reduction of malignant melanoma cell gro...

Study of Pathwork Diagnostics' Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases

SUNNYVALE, Calif., Dec. 14 /PRNewswire/ -- Pathwork Diagnostics, a genomics-based diagnostics company focused on oncology, announced that its Pathwork(R) Tissue of Origin Test is the focus of a study published in the January issue of The Journal of Molecular Diagnostics. Pathwork's genomics-ba...

Biocept Announces Study to Isolate Circulating Tumor Cells from Blood

SAN DIEGO, Dec. 3 /PRNewswire/ -- Biocept, an emerging leader in biotechnology, is initiating a collaborative study with the University of Texas M.D. Anderson Cancer Center to investigate the ability to isolate circulating tumor cells (CTCs) in blood. The study will use Biocept's proprietary C...

VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor

BASKING RIDGE, N.J., Nov. 26 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals (OTC Bulletin Board: VQPH) today announced the initiation of a Phase IIa study of Lenocta(TM) (sodium stibogluconate), a novel protein tyrosine phosphatase inhibitor, in combination with interferon alpha, an immune...

Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents

SAN FRANCISCO, Oct. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2007 AACR-NCI- EORTC International Conference in San Francisco that its integrin-targeted PI3 kinase inhibitor, SF1126, showed synergistic effects with certain s...

Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development

Cell Therapeutics, Inc. (CTI) announces data presented at AACR-NCI-EORTC Symposium SAN FRANCISCO, Oct. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a wholly-owned subsidiary of CTI, announced ne...

NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models

Anti-Tumor Activity of NKTR-102 Associated With Increased and Sustained Exposure of Tumor Tissue to the Active Metabolite of Irinotecan SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) presented positive preclinical data today on its proprietary product ...

Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers

Positive Results Prompt Phase 2 Trial of JX-594 in Liver and Head and Neck Cancers SAN FRANCISCO, Oct. 23 /PRNewswire/ -- Jennerex Biotherapeutics today presented clinical data from a Phase 1 / 2 trial of JX-594 -- the company's proprietary targeted lytic and immu...
Other Tags
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology , ... announced the availability of the VeriLook Surveillance ... 3.0 provides real-time biometric face identification using live ... surveillance cameras. The new version not only identifies ... people from objects while they are moving through ...
(Date:10/14/2014)... have sequenced the house fly genome for the first ... from an insect that thrives in pathogen-rich dung piles ... in the journal Genome Biology , will increase ... how flies quickly adapt to resist insecticides, which could ... (Musca domestica) carry and transmit more than 100 human ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... Dunbridge, Ohio (PRWEB) October 20, 2014 ... 50 years, takes pride in manufacturing top-of-the-line absorbent products. ... the image of its most popular brand, Tranquility® Premium ... logo, created a new website, gave its packaging a ... to bring the brand message to the public. , ...
(Date:10/20/2014)... CO (PRWEB) October 20, 2014 ... assays are the only imaging assays capable of ... a single test.  With these three dimensions of ... ability to detect the widest range of disease-causing ... usually missed by other genomic tools, including today’s ...
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... be introduced in the U.S., has a lot to celebrate ... when our country recognizes the achievements and contributions of Americans ... the anniversary for Punzoné, and today it shares its favorite ... take a trip to Italy - even if it is ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers ... bamboo deckings . Moreover, the company has launched ... now available at deeply discounted rates. , As ... overstate the significance of online business nowadays. Thus, BambooIndustry.com ... company’s workers are striving to deliver both value and ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
Other Contents